Asad Haider
Stock Analyst at Goldman Sachs
(1.64)
# 3,118
Out of 4,842 analysts
6
Total ratings
50%
Success rate
0.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Initiates: Neutral | $110 | $100.02 | +9.98% | 1 | May 29, 2025 | |
| JNJ Johnson & Johnson | Upgrades: Buy | $157 → $172 | $153.27 | +12.22% | 1 | Apr 9, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $720.92 | +23.18% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $185.54 | +4.56% | 1 | Apr 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Neutral | $67 → $55 | $47.64 | +15.45% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $23.37 | +6.97% | 1 | Apr 8, 2025 |
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $100.02
Upside: +9.98%
Johnson & Johnson
Apr 9, 2025
Upgrades: Buy
Price Target: $157 → $172
Current: $153.27
Upside: +12.22%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $720.92
Upside: +23.18%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $185.54
Upside: +4.56%
Bristol-Myers Squibb Company
Apr 8, 2025
Downgrades: Neutral
Price Target: $67 → $55
Current: $47.64
Upside: +15.45%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $23.37
Upside: +6.97%